JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312393

Alexa Fluor® 568 Anti-VEGFD 抗体 [EPR8457]

Alexa Fluor® 568 Anti-VEGFD antibody [EPR8457]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal VEGFD antibody - conjugated to Alexa Fluor® 568.

別名を表示する

FIGF, VEGFD, Vascular endothelial growth factor D, VEGF-D, c-Fos-induced growth factor

関連する標識済み抗体及び組成の異なる製品 (10)

  • Unconjugated

    Anti-VEGFD antibody [EPR8457]

  • 578 PE

    PE Anti-VEGFD antibody [EPR8457]

  • 660 APC

    APC Anti-VEGFD antibody [EPR8457]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-VEGFD antibody [EPR8457]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-VEGFD antibody [EPR8457]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-VEGFD antibody [EPR8457]

  • HRP

    HRP Anti-VEGFD antibody [EPR8457]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-VEGFD antibody [EPR8457]

  • Biotin

    Biotin Anti-VEGFD antibody [EPR8457]

  • Carrier free

    Anti-VEGFD antibody [EPR8457] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR8457

アイソタイプ

IgG

標識

Alexa Fluor® 568

励起波長/蛍光波長

Ex: 578nm, Em: 603nm

キャリアフリー

No

アプリケーション

Target Binding Affinity, Antibody Labelling

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

下記製品にもご興味をお持ちいただけるかもしれません:

AB233625

Human VEGF-D ELISA Kit

0

0 Reviews

製品ページを見る
こちらの製品も推奨する理由

この製品は、同様の実験や関連する研究で広く使用されていることから推奨させていただいております。

お客様の実験に適するかご確認いただくため、必ず製品データシートをご確認いただくことをお勧めいたします。ご不明点等ございましたら、テクニカルサポートチームまでお問い合わせください。

style
left-column

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

VEGFD also known as vascular endothelial growth factor D plays a role in angiogenesis and lymphangiogenesis by interacting with VEGF receptors. This protein has a molecular mass of approximately 32 kDa. It is typically expressed in the lungs heart skeletal muscle and small intestine. VEGFD undergoes several proteolytic processes to gain full activity highlighting its functional complexity in the body.
Biological function summary

Vascular endothelial growth factor D promotes the proliferation and migration of endothelial cells facilitating vascular formation and remodeling. It forms part of the VEGF protein family which is known for its involvement in various vascular processes. The protein's action is largely mediated through its binding to VEGFR-2 and VEGFR-3. This binding activates downstream signaling pathways that contribute to the growth and maintenance of blood and lymphatic vessels.

Pathways

The functioning of VEGFD is important in the vascular endothelial growth factor signaling pathway and the PI3K-Akt signaling pathway. These pathways are essential for the regulation of cellular processes such as survival growth and motility of endothelial cells. VEGFD is closely related to other members of the VEGF family including VEGFA and VEGFC which similarly interact with VEGF receptors to regulate vascular development and function.

Abnormal levels or activity of VEGFD can lead to pathological conditions such as cancer and lymphedema. In several cancers VEGFD is implicated in tumor angiogenesis aiding the tumor in acquiring nutrients and oxygen. Furthermore in lymphedema issues related to lymphatic vessel development can involve VEGFD alongside VEGFC contributing to fluid retention and tissue swelling. These associations highlight the importance of understanding VEGFD's functions in various pathological contexts.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
See full target information VEGFD
style
left-column
style
left-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。
style
left-column
style
right-column

関連製品

Select an associated product type
Alternative Version
Primary Antibodies

AB232447

Anti-VEGFD antibody [EPR8457] - BSA and Azide free

primary-antibodies

vegfd-antibody-epr8457-bsa-and-azide-free-ab232447

0

(0 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com